Your institution may have access to this item. Find your institution then sign in to continue.
Title
FDA Recommends Additional Data for Sparlon.
Abstract
Reports on the decision of the U.S. Food Drug and Administration's Psychopharmacologic Drug Advisory Committee not to give drug approval for Sparlon (modafinil) from Cephalon. Mechanism of action of the drug; Recommendation made by the committee to collect additional data to support the safety and efficacy of the drug in children and adolescent with attention-deficit/hypersensitivity disorder.